Principal Financial Group Inc Relay Therapeutics, Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$5.9 - $8.02 $66,050 - $89,783	-11,195 Reduced 43.43%	14,580 $95,000
Q1 2024 Apr 29, 2024	SELL	$7.5 - $12.07 $14,100 - $22,691	-1,880 Reduced 6.8%	25,775 $213,000
Q4 2023 Feb 07, 2024	SELL	$6.01 - $11.48 $16,882 - $32,247	-2,809 Reduced 9.22%	27,655 $304,000
Q3 2023 Nov 02, 2023	BUY	$8.24 - $12.97 $37,137 - $58,455	4,507 Added 17.36%	30,464 $256,000
Q2 2023 Aug 07, 2023	SELL	$9.99 - $18.27 $7,502 - $13,720	-751 Reduced 2.81%	25,957 $326,000
Q1 2023 May 09, 2023	BUY	$15.0 - $22.76 $45,300 - $68,735	3,020 Added 12.75%	26,708 $439,000
Q4 2022 Feb 09, 2023	BUY	$14.16 - $24.02 $43,046 - $73,020	3,040 Added 14.72%	23,688 $353,000
Q3 2022 Nov 09, 2022	BUY	$18.07 - $31.37 $70,454 - $122,311	3,899 Added 23.28%	20,648 $462,000
Q2 2022 Aug 10, 2022	SELL	$13.31 - $34.88 $76,173 - $199,618	-5,723 Reduced 25.47%	16,749 $280,000
Q1 2022 May 09, 2022	BUY	$20.26 - $32.36 $1,458 - $2,329	72 Added 0.32%	22,472 $673,000
Q4 2021 Feb 09, 2022	SELL	$26.0 - $37.03 $202,176 - $287,945	-7,776 Reduced 25.77%	22,400 $688,000
Q3 2021 Nov 09, 2021	BUY	$29.75 - $37.99 $9,698 - $12,384	326 Added 1.09%	30,176 $952,000
Q2 2021 Aug 10, 2021	BUY	$27.5 - $38.19 $581,542 - $807,603	21,147 Added 242.99%	29,850 $1.09 Million
Q1 2021 May 10, 2021	BUY	$32.52 - $61.53 $60,227 - $113,953	1,852 Added 27.03%	8,703 $301,000
Q4 2020 Feb 08, 2021	BUY	$35.51 - $54.03 $243,279 - $370,159	6,851 New	6,851 $285,000

204

156M

207K

40K

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $500M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.